Precise in vivo gene editing
Delivering CRISPR, base or prime editors to the right cells in a living body to change DNA precisely without harmful off-target effects.
State of the art
Casgevy approved 2023 (ex vivo); first personalized in vivo base-editing therapy given to an infant in 2025.
- Delivery to tissues beyond liver
- Long-term off-target safety
Who’s working on it
- Intellia Therapeutics ↗Company
Its Phase 3 HAELO trial of lonvo-z (NTLA-2002) in hereditary angioedema met the primary and all key secondary endpoints in April 2026, the first Phase 3 data for any in vivo gene-editing therapy
- David LiuResearcherBroad Institute of MIT and Harvard
Invented base and prime editing; his lab designed the base editor used for baby KJ in 2025 and is extending prime editing to disease-agnostic suppressor-tRNA approaches
- Kiran MusunuruResearcherUniversity of Pennsylvania and Children's Hospital of Philadelphia
Led the first patient-specific in vivo base-editing therapy, an LNP-delivered editor given to an infant with CPS1 deficiency (NEJM, May 2025), and is building umbrella platforms for urea-cycle disorders and PKU
NIH Common Fund program funding targeted delivery technologies, safety assays and platform clinical-trial pathways; it underwrote the preclinical work behind the KJ therapy
- Beam Therapeutics ↗Company
Running BEAM-302 for alpha-1 antitrypsin deficiency and in 2026 made in vivo LNP delivery its priority even for sickle cell disease, the clearest industry bet that in vivo beats ex vivo
- Capstan TherapeuticsStartup
Built targeted LNPs that reprogram T cells in vivo rather than in a facility; acquired by AbbVie in 2025 for about $2.1B, pricing extrahepatic delivery
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Tissue-targeted delivery vehicles (LNPs, engineered capsids) | $$$ $100M – $1B |
Depends on
A root node: no prerequisites modeled.